BioSpace News Archive

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,250,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $5.25 per ADS for gross proceeds of approximately $6.56 million.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock

OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 15,000 shares of its common stock to one new employee as an inducement material for accepting employment with OptiNose

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the closing of its previously announced public offering of 1,923,077 shares of its common stock at a public offering price of $91.00 per share.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the closing of its previously announced private placement of 4,560,928 shares of its common stock (or co

The Georgia Dental Association supports Governor Kemp’s Executive Order temporarily allowing Georgia licensed dentists to administer the COVID-19 vaccine at public health sites on a volunteer basis.

BridgeBio Pharma, Inc. announced the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Rise in the complexity and number of clinical trials is expected to support growth of the global central lab market over the forecast period, from 2020 to 2030.

Neurological disorders are at an all-time high and need to be controlled. Hence, this aspect may serve as a notable growth factor for the global delirium market across the forecast period of 2020-2030.